Ted Fjällman

Ted is Venture Partner in Flerie Invest, a Swedish investment firm and investor in Amarna, with biotech investments in Sweden, the UK, the Netherlands and Israel. He is also the CEO of Prokarium, a London-based biotech developing microbial immunotherapies and vaccines. Ted has held a clinical research position at Sahlgrenska University Hospital and has worked as a strategy consultant at Sweden’s Royal Academy of Engineering Sciences, where he coordinated the country’s national innovation strategy. He is an active member of the UK BioIndustry Association (BIA) and has served on the Management Board of the international Bacterial Vaccines Network (BactiVac). He also co-founded and continues to serve on the board of Tekiu, an international knowledge transfer broker active within healthcare, environmental tech and smart cities.

Ted holds a PhD in Biotechnology & Immunology from the university of Guelph, Canada.